Andrew L. Pecora, MD, CPE: If we take the premise that regardless of where you live, if you’re an American citizen, you should get the same level of care as any other American citizen and we look at the obvious inequalities of distribution of care throughout the country, and then you layer on top of that the complexity and expense of immuno-oncology, this is its own crisis flashpoint.
I’m actually a practicing immuno-oncologist. That’s what I did my research in and this is what I do every day. So, I see things I’ve never seen before. I see young people with metastatic melanoma and with brain metastases who have complete responses and they’re now 5 to 7 years out, they’re seemingly cured. It’s hundreds and hundreds of thousands of dollars to do that. It’s very complicated to give these drugs, and the side effect profiles of these drugs, if you don’t manage them right, can be deadly. So, you have this incredible, not incremental, benefit—but profoundly change-of-care benefit. And now, we have safety net hospitals that are struggling and you layer on top of that [the] alternative payment models. So, it sounds like you’re putting everything in a blender and hitting spin, right? How do you see, from your perspective, all of this tying out?
Brenton Fargnoli, MD: In the short run, a lot of the critical access hospitals, rural health clinics, and federally qualified health centers have been exempt from participation in models, such as the Oncology Care Model. In terms of immuno-oncology and combination immunotherapy, I agree: the promise and what we’ve seen with patients has been fantastic. And I think that’s the point—to key in on what it’s delivering, for certain patients, tremendous outcomes. So, there’s certainly an appetite among the various stakeholders to move toward some outcomes-based drug pricing. And [through] that lens, it then becomes quite feasible in terms of delivering tremendous outcomes for these particular patients.
The challenge becomes how to measure that in the real world. You can do clinical trials and cohort analyses and then say for this set of patients, “This is the cost.” But to efficiently and accurately do that at scale, leveraging real world data, to say, “The patient that Dr Pecora treated now is living 40 years longer,” there’s a price for that [outcome] versus, “The other patient Dr Pecora treated passed away a week later.” So, there’s an opportunity to look at different payment models, in that regard. And bringing it back to the patient will be key in terms of the outcomes the drug is actually delivering.
Rena M. Conti, PhD: I agree. I think the question is, who takes risks for those type of treatments? My view is that physicians shouldn’t be on the hook either way for patient benefit or patient costs associated with really new things, including the PD-1 (programmed cell death protein 1) inhibitors. But instead, really it’s pharmaceutical companies that should be holding some of this risk. So, moving toward paying for outcomes where pharma is providing drugs and some combination of insurers plus providers are providing data on real world outcomes (which is going to flow back to pharma in terms of payment and potentially to providers in some way in terms of some other payment) is where we’re going to go.
Those drugs are actually a great example where, frankly, we don’t really know which patients are going to respond perfectly to those treatments. And it’s entirely possible that we’re going to have to layer one drug on top of another drug in order to get durable responsivity. And so, in that case, it’s going to be very, very difficult for physicians and/or patients to be holding that risk. Someone else has to be holding the risk for that treatment, and it’s likely going to be some combination of the payers, the insurers, plus pharma.
Andrew L. Pecora, MD, CPE: That’s interesting. I agree. In our personal experience, we are now at the table with big data, precision analytics, payers, and pharma. We’re all figuring this out together. So, I think that’s going to be as transformative as anything we’ve talked about and that the pharmaceutical industry and the biotechnology industry are going to understand [that] the risk they’re taking is not just the risk of discovery and approval, it’s also the risk of efficacy in the real-world setting.
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
2 Commerce Drive
Cranbury, NJ 08512